Business: a leading global manufacturer of hard empty capsules. HQ: Basel, Switzerland
Joint Global Coordinators and Physical Bookrunners: GS (B&D), Jefferies, BNP, and UBS
Joint Bookrunners: BBVA, ING, IMI - Intesa Sanpaolo, RBI, SocGen, UniCredit, and Standard Chartered
Size: expected Min €500m
Format: 144A/Reg S
Instrument: Senior Secured Notes
Ratings: B1/B+ (stable/stable)
Use of Proceeds: along with proceeds from equity contribution, and a USD/EUR term loan B 2-part (USD$500m minimum and EUR500m minimum) (total loan and bond deal size CHF1.38bn equivalent). to fund the CHF2bn purchase price for the acquisition of a 60% interest in Capsugel by Lone Star from Lonza Group AG (which will retain a 40% minority interest) and provide for cash overfunding to the balance sheet.
Tenor: 7 year
Call Schedule: NC3 (MWC B+50bp) (50%,25%,par). Equity claw: 3y 40%. Special call: 10% per year the first 2 years at 103
List: ISE
Law: NY
Denoms: 100kx1k
Equity sponsor: Lone Star
Equity contribution: CHF823m, including Lonza's rollover equity.
Roadshow (virtual meetings): start 27-Apr-26
Global Investor Call: 15:00 UKT / 10:00 ET 27-Apr-26
Netroadshow direct link: https://urldefense.com/v3/__https:/www.netroadshow.com/nrs/home/*!/?show=bf5c1c4a__;Iw!!O2kDR7mm-zSJ!qLX_5QW9_uiWcE1TqrJb7_o9abmY_G1Q4QE5RlkdmcUCeJrQVHEt6nuDc7Uf9_cQ-R_CV7_u0AZ94gc$